Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy

References

• CapriSCeciATerranovaLGuidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studiesDrug Inf J200135189201
   Web of Science ®Google Scholar
• CIBIS-II Investigators and Health Economics Group*Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II)Eur Heart J20012210213111428837
   PubMed Web of Science ®Google Scholar
• CookJDrummondMHeyseJFEconomic endpoints in clinical trialsStat Methods Med Res200441321577615068259
   PubMed Web of Science ®Google Scholar
• CovinskyKEPalmerRMFortinskyRHLoss of independence in activities of daily living in older adults hospitalized with medical illnesses: increased vulnerability with ageJ Am Geriatr Soc200351451812657063
   PubMed Web of Science ®Google Scholar
• GarattiniLGrilliRScopellitiDA proposal for Italian Guidelines in pharmacoeconomicsPharmacoeconomics199571610155289
   PubMed Web of Science ®Google Scholar
• GlickHCookJKinosianBCosts and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment TrialJ Card Fail199513718012836712
   PubMedGoogle Scholar
• GlickHAOrzolSMTooleyJFEconomic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failureCardiovasc Drugs Ther20021653912085979
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJYusufSEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialLancet2003362772613678870
   PubMed Web of Science ®Google Scholar
• Instituto Nazionale di Statistica2007 URL: http://demo.istat.it/index_e.html
   Google Scholar
• Jimenez-NavarroMFMunoz GarciaAJGarcia-PinillaJMTrends of hospitalizations for chronic heart failure in Andalusia in the last decadeRev Clin Esp2006206474617129514
   PubMed Web of Science ®Google Scholar
• KoellingTMChenRSLubwamaRNThe expanding national burden of heart failure in the United States: the influence of heart failure in womenAm Heart J200414774814691422
   PubMed Web of Science ®Google Scholar
• LimSCDoshiVCastasusBFactors causing delay in discharge of elderly patients in an acute care hospitalAnn Acad Med Singapore200635273216470271
   PubMed Web of Science ®Google Scholar
• MauskopfJAPaulJEGrantDMThe role of cost-consequence analysis in healthcare decision-makingPharmacoeconomics1998132778810178653
   PubMed Web of Science ®Google Scholar
• MazzaATikhonoffVCasigliaPredictors of congestive heart failure mortality in elderly people from the general populationInt Heart J2005464193116043938
   PubMed Web of Science ®Google Scholar
• McMurrayJDavieAThe pharmacoeconomics of ACE inhibitors in chronic heart failurePharmacoeconomics199691889710160096
   PubMed Web of Science ®Google Scholar
• McMurrayJJVPetrieMCMurdochDRClinical epidemiology of heart failure: public and private health burdenEur Heart J199819916
   Web of Science ®Google Scholar
• McMurrayJOstergrenJPfefferMClinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programmeEur J Heart Fail2003a52617012798823
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet2003b3627677113678869
   PubMed Web of Science ®Google Scholar
• McMurrayJJAnderssonFLStewartSResource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeEur Heart J20062714475816754631
   PubMed Web of Science ®Google Scholar
• O’MearaESolomonSMcMurrayJEffect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeEur Heart J2004251920615522471
   PubMed Web of Science ®Google Scholar
• PaulSDKuntzKMEagleKACosts and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failureArch Intern Med1994154114398185426
   PubMedGoogle Scholar
• PfefferMASwedbergKGrangerCBEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet20033627596613678868
   PubMed Web of Science ®Google Scholar
• ReedSDAnstromKJBakhaiAConducting economic evaluations alongside multinational clinical trials. Toward a research consensusAmn Heart J200514943443
   PubMed Web of Science ®Google Scholar
• SeguinPLaviolleBChanavazCFactors associated with multidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapyClin Microbiol Infect200612980516961634
   PubMed Web of Science ®Google Scholar
• SEOSI InvestigatorsSurvey on heart failure in Italian hospital cardiology units. Results of the SEOSI studyEur Heart J1997181457649458452
   PubMed Web of Science ®Google Scholar
• SwedbergKPfefferMGrangerCCandesartan in heart failure – assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme InvestigatorsJ Card Fail199952768210496201
   PubMedGoogle Scholar
• United Nations, Statistical OfficeDemographic Yearbook1991New YorkUnited Nations
   Google Scholar
• VilellaAPratABareMLBayasJMRisk of nosocomial infection in elderly patients admitted to a university hospital [Spanish]Med Clin (Barc)199310012831
   Google Scholar
• WhiteHDCandesartan and heart failure: the allure of CHARMLancet2003362754513678864
   PubMed Web of Science ®Google Scholar
• YoungJBDunlapMEPfefferMAMortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trialsCirculation2004110261826 Epub 2004 Oct 1815492298
   PubMed Web of Science ®Google Scholar
• YusufSPfefferMASwedbergKEffects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialLancet20033627778113678871
   PubMed Web of Science ®Google Scholar